Table 5

Differences between high-risk and low-risk patients’ preferences for osteoporosis drug treatment
Attributes and levels High risk patients Low-risk patients P valuea
(FRAX major >10%) (FRAX major ≤10%)
Number of patients 139 114
Pseudo-R2 0.39 0.42
Log-likelihood -1,378.35 -1,085.55
Constant 1.50*** (1.17 to 1.83) -0.05 (–0.52 to 0.43) 0.01
Efficacy (1% risk reduction) 0.04*** (0.03 to 0.04) 0.14*** (0.11 to 0.17) 0.00
SD: 1.65*** SD: 1.01***
Cost per month (€1) -0.02*** (–0.02 to –0.03) -0.08*** (–0.06 to –0.09) 0.00
SD: 1.45*** SD: 0.67***
Drug administration (reference level: weekly oral tablet)
 Monthly oral tablet 0.57** (0.08 to 1.06) 1.14*** (0.47 to 1.82) 0.14
SD: 0.94*** SD: 1.87***
 Subcutaneous injection 3-monthly 0.14 (–0.19 to 0.47) 0.28 (–0.17 to 0.74) 0.14
SD: NS SD: NS
 Subcutaneous injection 6-monthly 0.57*** (0.17 to 0.96) 1.55*** (0.97 to 2.14) 0.06
SD: NS SD: NS
 Intravenous injection 3-monthly -0.28 (–0.88 to 0.31) -0.24 (–1.39 to 0.91) 0.25
SD: 1.82*** SD: 4.84***
 Intravenous injection yearly 0.28 (–0.13 to 0.69) 0.75** (0.05 to 1.45) 0.33
SD: 0.81*** SD: 2.15***
Side effects (reference level: gastrointestinal disorders)
 Flu-like symptoms 0.66*** (0.36 to 0.95) 1.51*** (1.07 to 1.95) 0.57
SD: 0.91*** SD: 1.18***
 Skin reactions 0.45** (0.05 to 0.85) 0.49** (0.10 to 0.87) 0.05
SD: 1.31*** SD: 1.04***

Data presented as estimate (95% confidence interval). SD, standard deviation; NS, not significant. aP value was estimated in a joint model with interaction terms. **P < 0.05. ***P < 0.01.

Hiligsmann et al.

Hiligsmann et al. Arthritis Research & Therapy 2014 16:R36   doi:10.1186/ar4465

Open Data